CD36 and atherosclerosis

CD36 has been associated with diverse normal and pathologic processes. These include scavenger receptor functions (uptake of apoptotic cells and modified lipid), lipid metabolism and fatty acid transport, adhesion, angiogenesis, modulation of inflammation, transforming growth factor-β activation, atherosclerosis, diabetes and cardiomyopathy. Although CD36 was identified more than 25 years ago, it is only with the advent of recent genetic technology that in-vivo evidence has emerged for its physiologic and pathologic relevance. As these in-vivo studies are expanded, we will gain further insight into the mechanism(s) by which CD36 transmits a cellular signal, and this will allow the design of specific therapeutics that impact on a particular function of CD36.

[1]  T. Kurtz,et al.  Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. , 1999, The Journal of clinical investigation.

[2]  R. Mittler,et al.  Classification of human lymphocytes and monocytes with the OK series of monoclonal antibodies. , 1983, Diagnostic immunology.

[3]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[4]  J. Peters,et al.  Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. , 1998, The Journal of biological chemistry.

[5]  K. Kawamura,et al.  Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? , 1997, Journal of molecular and cellular cardiology.

[6]  Judith A. Blake,et al.  The Mouse Genome Database (MGD): expanding genetic and genomic resources for the laboratory mouse , 2000, Nucleic Acids Res..

[7]  Jihong Han,et al.  Native and Modified Low Density Lipoproteins Increase the Functional Expression of the Macrophage Class B Scavenger Receptor, CD36* , 1997, The Journal of Biological Chemistry.

[8]  F. Sherman,et al.  Degradation of Cytochrome Oxidase Subunits in Mutants of Yeast Lacking Cytochrome c and Suppression of the Degradation by Mutation of yme1(*) , 1995, The Journal of Biological Chemistry.

[9]  D. Gómez-Coronado,et al.  Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. , 1998, Journal of lipid research.

[10]  J Savill,et al.  Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. , 1992, The Journal of clinical investigation.

[11]  Seth M. Klein,et al.  Comparison of Class B Scavenger Receptors, CD36 and Scavenger Receptor BI (SR-BI), Shows That Both Receptors Mediate High Density Lipoprotein-Cholesteryl Ester Selective Uptake but SR-BI Exhibits a Unique Enhancement of Cholesteryl Ester Uptake* , 1999, The Journal of Biological Chemistry.

[12]  Y. Tomiyama,et al.  A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). , 1990, Blood.

[13]  S. Schultz-Cherry,et al.  The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. , 1994, The Journal of biological chemistry.

[14]  F. Sánchez‐Madrid,et al.  Gene encoding the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2. , 1993, Genomics.

[15]  R. Silverstein,et al.  A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism* , 1999, The Journal of Biological Chemistry.

[16]  A. Bonen,et al.  Muscle-specific Overexpression of FAT/CD36 Enhances Fatty Acid Oxidation by Contracting Muscle, Reduces Plasma Triglycerides and Fatty Acids, and Increases Plasma Glucose and Insulin* , 1999, The Journal of Biological Chemistry.

[17]  E. Brown,et al.  Integrin-associated Protein Is a Receptor for the C-terminal Domain of Thrombospondin (*) , 1996, The Journal of Biological Chemistry.

[18]  J. Isner,et al.  Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. , 1998, American heart journal.

[19]  J. Wu,et al.  Thrombospondin: Evidence for a Single Transmembrane Domain a Carboxyl Terminal Truncation Mutant of Cd36 Is Secreted and Binds , 2022 .

[20]  R. Silverstein,et al.  Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.

[21]  C. Ockenhouse,et al.  Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. , 1989, Science.

[22]  V. Dixit,et al.  The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. , 1985, The Journal of biological chemistry.

[23]  O. Volpert,et al.  Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. , 1999, Molecular pharmacology.

[24]  R. Voll,et al.  Immunosuppressive effects of apoptotic cells , 1997, Nature.

[25]  Jihong Han,et al.  Lipoproteins modulate expression of the macrophage scavenger receptor. , 1998, The American journal of pathology.

[26]  K. Kawamura,et al.  CD36 abnormality and impaired myocardial long-chain fatty acid uptake in patients with hypertrophic cardiomyopathy. , 1998, Japanese circulation journal.

[27]  R. Silverstein,et al.  Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. , 1987, The Journal of clinical investigation.

[28]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[29]  G. Jamieson,et al.  Platelet glycocalicin. I. Orientation of glycoproteins of the human platelet surface. , 1976, The Journal of biological chemistry.

[30]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.

[31]  D. Greenwalt,et al.  Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. , 1995, The Journal of clinical investigation.

[32]  L. Yesner,et al.  Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. , 1996, Blood.

[33]  S. Ryeom,et al.  Binding of Anionic Phospholipids to Retinal Pigment Epithelium May Be Mediated by the Scavenger Receptor CD36* , 1996, The Journal of Biological Chemistry.

[34]  D. Mendrick,et al.  Identification of integrin alpha 3 beta 1 as a neuronal thrombospondin receptor mediating neurite outgrowth. , 1995, Neuron.

[35]  N. Abumrad,et al.  Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. , 1999, Biochimica et biophysica acta.

[36]  R. Silverstein,et al.  Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. , 1989, The Journal of clinical investigation.

[37]  James Scott,et al.  Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats , 1999, Nature Genetics.

[38]  M. Kodama,et al.  Hypertrophic cardiomyopathy with type I CD36 deficiency. , 1998, Japanese circulation journal.

[39]  Kenichi Watanabe,et al.  Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency , 1998, Annals of nuclear medicine.

[40]  S. Mai,et al.  Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. , 1999, The American journal of pathology.

[41]  J. Barnwell,et al.  Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain. , 1993, Science.

[42]  M. Krieger,et al.  The other side of scavenger receptors: pattern recognition for host defense , 1997, Current opinion in lipidology.

[43]  S. Souza,et al.  BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. , 1998, Diabetes.

[44]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[45]  V. Fadok,et al.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. , 1998, The Journal of clinical investigation.

[46]  W. Ling,et al.  High Affinity Saturable Uptake of Oxidized Low Density Lipoprotein by Macrophages from Mice Lacking the Scavenger Receptor Class A Type I/II* , 1997, The Journal of Biological Chemistry.

[47]  R. Silverstein,et al.  Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[48]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[49]  A. Rusiñol,et al.  Isolation of a Somatic Cell Mutant Resistant to the Induction of Apoptosis by Oxidized Low Density Lipoprotein* , 2000, The Journal of Biological Chemistry.

[50]  G. V. van Eys,et al.  Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. , 1995, Biochemical and biophysical research communications.

[51]  T. Mikkelsen,et al.  Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.

[52]  R. F. Cook,et al.  Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease , 1994, The Journal of cell biology.

[53]  A. Gotto,et al.  Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. , 2000, Journal of lipid research.

[54]  R. Silverstein,et al.  Recombinant Glutathione S-Transferase/CD36 Fusion Proteins Define an Oxidized Low Density Lipoprotein-binding Domain* , 1998, The Journal of Biological Chemistry.

[55]  T. Nakata,et al.  Scintigraphic evidence for a specific long-chain fatty acid transporting system deficit and the genetic background in a patient with hypertrophic cardiomyopathy. , 1999, Japanese circulation journal.

[56]  J. Loike,et al.  Complementary Roles for Scavenger Receptor A and CD36 of Human Monocyte–derived Macrophages in Adhesion to Surfaces Coated with Oxidized Low-Density Lipoproteins and in Secretion of H2O2 , 1998, The Journal of experimental medicine.

[57]  S. Gordon,et al.  Recognizing death: the phagocytosis of apoptotic cells. , 1998, Trends in cell biology.

[58]  O. Volpert,et al.  A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  W. Vainchenker,et al.  A monoclonal antibody against an erythrocyte ontogenic antigen identifies fetal and adult erythroid progenitors. , 1986, Blood.

[60]  J. Dopazo,et al.  The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. , 1995, Genomics.

[61]  D. Mosher,et al.  Interaction of Recombinant Procollagen and Properdin Modules of Thrombospondin-1 with Heparin and Fibrinogen/Fibrin* , 1999, The Journal of Biological Chemistry.

[62]  A. Rigotti,et al.  Sterol Carrier Protein-2 Is Involved in Cholesterol Transfer from the Endoplasmic Reticulum to the Plasma Membrane in Human Fibroblasts (*) , 1995, The Journal of Biological Chemistry.

[63]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[64]  P. Grimaldi,et al.  Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[65]  S. Ryeom,et al.  CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. , 1996, Journal of cell science.

[66]  J. Takagi,et al.  A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin. , 1993, The Journal of biological chemistry.

[67]  K. Dameron,et al.  The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.

[68]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[69]  Brian Seed,et al.  CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes , 1989, Cell.

[70]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[71]  R. Silverstein,et al.  Lysosomal Integral Membrane Protein II Binds Thrombospondin-1 , 1998, The Journal of Biological Chemistry.

[72]  R. Hynes,et al.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo. , 1998, Cell.

[73]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[74]  F. V. van Nieuwenhoven,et al.  Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[75]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[76]  P. Grimaldi,et al.  Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. , 1993, The Journal of biological chemistry.

[77]  K. Matsumoto,et al.  Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[78]  Tsutomu,et al.  CD 36 mediates long-chain fatty acid transport in human myocardium : Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD 36 deficiency , 2022 .

[79]  B. Podolsak Effects of Thrombin, Chymotrypsin and Aggregated Gamma-Globulins on the Proteins of the Human Platelet Membrane , 1977, Thrombosis and Haemostasis.

[80]  R. Aster,et al.  Incidence of the Nak(a)‐negative platelet phenotype in African Americans is similar to that of Asians , 1996, Transfusion.

[81]  S. Schultz-Cherry,et al.  Transforming growth factor-beta complexes with thrombospondin. , 1992, Molecular biology of the cell.

[82]  J. Murphy-Ullrich,et al.  Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. , 2000, Cytokine & growth factor reviews.

[83]  P. Delmas,et al.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.

[84]  S. Ryeom,et al.  CD 36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium , 1996 .

[85]  J. Lawler The structural and functional properties of thrombospondin. , 1986, Blood.

[86]  M. Lagueux,et al.  Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. , 1996, Immunity.

[87]  S. Yamashita,et al.  Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. , 1995, The Journal of clinical investigation.

[88]  Jun Wu,et al.  Recombinant GST/CD36 Fusion Proteins Define a Thrombospondin Binding Domain , 1995, The Journal of Biological Chemistry.

[89]  S. Yamashita,et al.  Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency). , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  R. Silverstein,et al.  Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[91]  A. Ludlow,et al.  Activation of Platelet-transforming Growth Factor β-1 in the Absence of Thrombospondin-1* , 2000, The Journal of Biological Chemistry.

[92]  D. Mendrick,et al.  Identification of integrin α 3 β 1 as a neuronal thrombospondin receptor mediating neurite outgrowth , 1995, Neuron.

[93]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[94]  J. Murphy-Ullrich,et al.  Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology , 2000 .

[95]  Jihong Han,et al.  Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. , 1999, Journal of lipid research.

[96]  A. Jochen,et al.  Purification of the major substrate for palmitoylation in rat adipocytes: N-terminal homology with CD36 and evidence for cell surface acylation. , 1993, Journal of lipid research.

[97]  L. Stanton,et al.  CD36 is a receptor for oxidized low density lipoprotein. , 1993, The Journal of biological chemistry.

[98]  A. Gotto,et al.  Transforming Growth Factor-β1 (TGF-β1) and TGF-β2 Decrease Expression of CD36, the Type B Scavenger Receptor, through Mitogen-activated Protein Kinase Phosphorylation of Peroxisome Proliferator-activated Receptor-γ* , 2000, The Journal of Biological Chemistry.

[99]  E. Brown,et al.  The Thrombospondin Receptor Integrin-associated Protein (CD47) Functionally Couples to Heterotrimeric Gi * , 1999, The Journal of Biological Chemistry.

[100]  I. Yuhanna,et al.  High Density Lipoprotein Prevents Oxidized Low Density Lipoprotein-induced Inhibition of Endothelial Nitric-oxide Synthase Localization and Activation in Caveolae* , 2000, The Journal of Biological Chemistry.

[101]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[102]  A. Rigotti,et al.  The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids (*) , 1995, The Journal of Biological Chemistry.

[103]  P. Grimaldi,et al.  Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[104]  F. Kamp,et al.  How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids? , 1999, Diabetes.

[105]  K. Nakajima,et al.  Absent myocardial I-123 BMIPP uptake in a family , 1996, Annals of nuclear medicine.

[106]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[107]  R. Silverstein,et al.  CD36 Induction on Human Monocytes upon Adhesion to Tumor Necrosis Factor-activated Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[108]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[109]  S. Hazen,et al.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. , 2000, The Journal of clinical investigation.

[110]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[111]  Joseph,et al.  Regulated Expression of CD 36 During Monocyte-to-Macrophage Differentiation : Potential Role of CD 36 in Foam Cell Formation , 2002 .